Aquestive Therapeutics (NASDAQ: AQST) is one of 546 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Aquestive Therapeutics to related companies based on the strength of its dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
This table compares Aquestive Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aquestive Therapeutics Competitors||-1,776.08%||-105.48%||-28.48%|
This is a summary of recent recommendations for Aquestive Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aquestive Therapeutics Competitors||4499||12939||27592||991||2.54|
Aquestive Therapeutics currently has a consensus target price of $23.60, indicating a potential upside of 290.73%. As a group, “Pharmaceutical preparations” companies have a potential upside of 52.34%. Given Aquestive Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than its competitors.
Valuation & Earnings
This table compares Aquestive Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aquestive Therapeutics||$67.43 million||-$61.38 million||-2.16|
|Aquestive Therapeutics Competitors||$2.17 billion||$229.91 million||-3.77|
Aquestive Therapeutics’ competitors have higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
66.0% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Aquestive Therapeutics beats its competitors on 8 of the 12 factors compared.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.